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T he poor fidelity of HIV genome replication is ad-vantageous to the virus, allowing the evolutionof mutant forms resistant to therapeutic agents.
About 50% of infected individuals are believed to har-
bor drug-resistant strains of HIV (1), highlighting the
need for new therapeutic strategies (2). HIV recruits host
cell proteins to mediate functions necessary for viral
propagation (for review, see refs 3 and 4. Such host pro-
teins offer points of possible antiviral interventions that
are alternatives to therapies aimed directly at the virus
and thus may be less subject to circumvention by viral
mutation (4).
To complete the viral life cycle, HIV particles as-
semble on and subsequently are released from the
plasma membrane of infected cells (5, 6). Release of
the virus requires the virally encoded Gag protein (7, 8),
plus the active participation of multiple host proteins
(5, 9). The p6 region of Gag, known as the late budding
domain, contains a highly conserved P(T/S)AP tetrapep-
tide motif that is essential for the viral budding event
(10, 11). This motif specifically interacts with the UEV
(ubiquitin E2 variant) domain of the host protein
TSG101 (12−14). TSG101, which was identified initially
as a tumor susceptibility gene protein (15), is a central
component of the endocytic machinery (16) that nor-
mally binds to the endosomal protein HRS (hepatocyte
growth factor-regulated tyrosine kinase substrate),
through a PSAP motif (17, 18). By mimicking the bind-
ing of HRS through its own PTAP motif, HIV Gag recruits
TSG101 and associated endocytic complex proteins to
theplasmamembrane tomediate viral release (19). Nor-
mal cellular levels of TSG101 are required for the bud-
ding of HIV, as inhibition of TSG101 synthesis or overex-
pression of the gene severely impairs virus production
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ABSTRACT The egress of HIV particles from virus-infected cells is accomplished
by the recruitment of proteins that normally mediate host cell endocytic functions.
This process requires interaction of the HIV Gag protein with the host protein
TSG101 (tumor susceptibility gene 101). Here, we report the use of a bacterial
reverse two-hybrid system to identify cyclic peptides that interfere with the
Gag!TSG101 interaction and the finding that a five amino acid peptide discov-
ered by this approach can disrupt the interaction and consequently inhibit HIV
egress. The inhibiting molecule, which was selected from a cyclic peptide library
containing"3.2# 106 members, differs in primary sequence from the interacting
sites of either TSG101 or Gag. Addition of cyclic peptide tagged with an HIV Tat se-
quence, which previously has been shown to enhance protein translocation across
plasma membranes, to cultured human cells inhibited the production of virus-like
particles (VLPs) by these cells (IC50 of 7 $M), and this inhibition occurred in the ab-
sence of adverse affects on normal endocytic functions mediated by TSG101. A mu-
tant Gag protein not dependent on TSG101 for release was unaffected by the cy-
clic peptide. Our findings, which suggest that interference with the TSG101!Gag
interaction by cyclic peptides may be of practical use in the treatment of HIV infec-
tions, identify a specific cyclic peptide that reduces VLP release by this mechanism;
they also demonstrate that the efficiency of interference with protein!protein
interactions by cyclic peptides can be enhanced by tagging the peptides with
translocation-promoting sequences. Collectively our results support the notion
that small molecule therapeutics that inhibit specific interactions between viral
and host proteins may have general applicability in antiviral therapy.
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by arresting the release of viral particles from theplasma
membrane of host cells (12, 20). Furthermore, muta-
tions in motifs of either TSG101 or Gag that are essen-
tial for the interaction of these proteins also reduce the
production of infectious viral particles (12, 13). The
Gag!TSG101 interaction thus offers a potential target
for antiviral therapy. Recently, Burke and colleagues
(21, 22) have generated chemically modified PTAP-
containing peptides with enhanced affinity for TSG101
in an effort to develop inhibitors of Gag!TSG101
interaction.
A previously reported method enables genetic
selection of cyclic peptide inhibitors of protein!
protein interactions; the methodology combines
SICLOPPS (split intein-mediated circular ligation of pep-
tides and proteins) libraries (23, 24) with a bacterial
RTHS (reverse two-hybrid system). SICLOPPS is a ro-
bust and flexible method for the biosynthesis of small
molecule libraries; a plasmid library is constructed (with
degenerate oligonucleotides) coding for the C- and
N-terminus of the Synechocystis sp. PCC6803 DnaE
split inteins, joined by a predetermined number of ran-
dom (or intermittently random) amino acids. After intra-
cellular expression, the split inteins process to give a cy-
clic peptide (Figure 1, panel a). The cyclic peptide library
can contain up to a hundred million (108) members
(25, 26). The bacterial RTHS (25, 26) is based on the
bacteriophage regulatory system, using chimeric repres-
sor fusions and promoter sequences to link the disrup-
tion of targeted fusion protein heterodimers to the ex-
pression of three reporter genes. HIS3 (imidazole
glycerol phosphate dehydratase) and KanR (aminoglyco-
side 3=-phosphotransferase for kanamycin resistance)
are two chemically tuneable, conditionally selective re-
porter genes. The third reporter gene, LacZ (%-galacto-
sidase), is used to quantify the protein!protein interac-
tion through %-galactosidase assays. The combined
SICLOPPS/RTHS system thus can identify cyclic peptide
inhibitors and concurrently reveal the relative affinity
and selectivity of each inhibitor.
We used SICLOPPS/RTHS to identify novel cyclic pep-
tides that disrupt the Gag!TSG101 interaction. Here
Figure 1. Schematic summary of the procedures used for cyclic peptide production and reverse two-hybrid screening. a) The SICLOPPS plasmid
codes for a split intein that folds to form an active intein, which undergoes a series of rearrangements to generate a cyclic peptide. In this case
each SICLOPPS plasmid codes for a target cyclic peptide with randomly encoded amino acids forming libraries of"108 members. Z" S or O (cys-
teine or serine). b) Bacterial reverse two-hybrid system. Top panel: The target proteins are expressed as fusions with the 434 or P22.434 bacteri-
ophage DNA binding proteins, which associate to form a functional repressor that prevents expression of the reporter genes (inhibiting growth on
minimal media). Bottom panel: A small molecule inhibits the protein!protein interaction of the target proteins (p6 and UEV), allowing transcription
and translation of the reporter genes that rescue growth by induction of HIS3 and KanR. #-Galactosidase assays were used to quantify repression
of lacZ expression. c) ONPG assay of the p6!UEV reverse two-hybrid system. The data shows increasing IPTG levels (increased expression of the
fusion proteins that dimerize to form a functional repressor) resulting in reduced activity of the LacZ reporter gene product (#-galactosidase), as
quantified by monitoring the cleavage of ONPG. This confirms the dimerization of UEV and p6 in our reverse two-hybrid system. The optimal IPTG
level for genetic selection was determined to be 30 mM, the minimum level at which intracellular fusion protein concentration is sufficient to form a
functional repressor.
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we report that an eight-member cyclic peptide that had
similar effects on disruption of the Gag!TSG101 and
HRS!TSG101 interaction inhibited release of virus-like
particles (VLPs) when translocated into VLP-producing
cells, while still allowing normal endocytosis. Our results
provide evidence for the therapeutic potential of small
molecule interference with virus-recruited host protein
functions.
RESULTS ANDDISCUSSION
Since the p6 region of HIV Gag and the UEV domain of
TSG101 are both necessary and sufficient for the
Gag!TSG101 interaction, we introduced DNA frag-
ments encoding the p6 region of Gag and the UEV do-
mainof TSG101 into theRTHSplasmidand cloned these
constructs in E. coli. Expression of the gene fragments
was under the control of an isopropyl %-D-thiogalacto-
side (IPTG) inducible promoter (Figure 1, panel b). To
eliminate false selections arising from plasmid ejection,
the cassette coding for the p6-P22.434 and UEV-434 re-
pressor fusion proteins was integrated into the chromo-
some of an E. coli reporter strain by previously reported
methods (26, 27). Upon chromosomal integration of
the p6!UEV reverse two-hybrid system, o-nitrophenyl-
%-galactoside (ONPG) assays were carried out to mea-
sure the IPTG-dependent repression of the LacZ gene
product (%-galactosidase). Increased IPTG-dependent
expression of the fusion proteins resulted in decreased
%-galactosidase activity (Figure 1, panel c), indicating
that UEV and p6 interact in our reverse two-hybrid
system.
To identify cyclic peptides that may inhibit the
p6!UEV interaction, we constructed a SICLOPPS library
using oligonucleotides that encode for cyclic peptides of
type SGWXXXXX (X& any amino acid). The invariable
motif of the peptide was designed to contain serine
(a required nucleophile for intein processing), glycine
(to avoid racemization during chemical synthesis), and
tryptophan, which functions as a chromophore for HPLC
purification. After electroporation of the SICLOPPS plas-
mid library into E. coli (DH5'), we obtained"4# 108
colonies, giving good coverage of our cyclic peptide li-
brary (3.2# 106 six-member cyclic peptides, with five
random residues). Isolated plasmids from this library
were transformed into the selection strain (1# 108
transformants) and plated onto histidine-free minimal
media at a density of 106 per plate (100mm# 15mm).
The selection plates were supplemented with arabi-
nose (inducer for SICLOPPS), 3-amino-1,2,4-triazole
(3-AT, competitive inhibitor of HIS3 gene product), and
kanamycin. The plates were incubated until colonies
were readily visible ("1 in 105). Approximately 100
colonies were picked and screened for IPTG-dependent
growth inhibition and arabinose-dependent growth ad-
vantage in order to eliminate false positives. The ex-
pected phenotype was further confirmed by isolating
and retransforming the selected SICLOPPS plasmids
into the p6!UEV selection strain. After several rounds
of secondary screening, we identified four cyclic pep-
tides that potentially inhibit the UEV!p6 interaction
(Table 1).
It is noteworthy that none of the identified cyclic pep-
tides has a primary sequence resembling P(S/T)AP.
However, as the Gag!TSG101 interaction is known to
be mediated by PTAP (28), we also constructed a
SICLOPPS library that mimicked this motif (SGWXXPXX-
PXX). The new library was introduced by transformation
into the p6!UEV selection strain (108 transformants).
Six colonies were identified after two rounds of screen-
ing. The cyclic peptide inhibitors (from both libraries)
were ranked for their activity to confer growth advan-
tage by spotting 10-fold serial dilutions of the corre-
sponding cells onto selective media (Table 1).
There is a certain degree of homology among the
amino acid sequences of the three cyclic peptides that
showed the greatest inhibition. Threonine is favored at
TABLE 1. Sequence of the genetically
selected cyclic peptide inhibitors of
p6!UEV dimerization, in order of
biological activity
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position one and tryptophan at position three. An inter-
esting occurrence is the presence of the NWY motif in
the top two peptides (but in reverse order in the second
peptide), suggesting that the same structural feature is
being targeted by both inhibitors. The inhibitory cyclic
peptides obtained from the PTAP targeted library were
not studied further, as they were less active as inhibi-
tors than those from the fully randomized library. This
finding, which argues that the cyclic peptide does not
act simply as a peptomimetic, suggests that themecha-
nism underlying the disruption of the TSG101!Gag in-
teraction is likely to be conformationally based. To as-
sess the specificity of the genetically selected cyclic
peptides for the p6!UEV interaction, the correspond-
ing SICLOPPS plasmids were introduced into a RTHS
strain used previously to select for inhibitors of the large
and small subunits of murine ribonucleotide reductase
(RR) (25). Specific p6!UEV inhibitors are expected to be
inactive in the RR strain, which was identical to the
p6!UEV selection strain except for the target protein
dimer. Three of the four selected peptides (peptides 6,
11, and 16) did not confer a growth advantage
(arabinose-dependent) on the RR strain and were there-
fore considered likely to be specific inhibitors for the
p6!UEV interaction.
As HIV budding is dependent on the protein!protein
interaction between TSG101 and Gag, we turned our at-
tention to assaying the cyclic peptide inhibitor’s ability
to interferewithHIV budding inmammalian cells. To this
end, cyclic peptides 6, 11, and 16 were chemically syn-
thesized and purified using previously described solid-
phase chemistry (26). The synthetic peptides were iden-
tical to the corresponding biologically produced
SICLOPPS peptides, as shown by both reverse-phase
HPLC and matrix-assisted laser desorption/ionization
(MALDI) mass spectrometry.
We used a Gag VLP (viral-like particle) assay to moni-
tor the effects of the cyclic peptides on viral budding.
The assay is basedon the finding that HIVGagprotein it-
self is sufficient to bud from the cell surface and give
rise to VLPs that aremorphologically similar to bona fide
virus particles (6, 8, 29). Human embryonic kidney 293T
cells were transfected with a Gag-GFP fusion construct
(30) and incubated inmedia containing one of the three
cyclic peptides (10$M). Forty-eight hours after transfec-
tion initiation, cell lysates and viral-like particles were
collected and analyzed by Western blotting.
Notwithstanding the observed ability of cyclic pep-
tides generated intracellularly to interfere with interac-
tion between TSG101 and Gag, we observed no effects
of the peptides on Gag-mediated VLP release when the
same peptides were added to culture media at concen-
trations up to 25 $M.We hypothesized that this finding
could be due to the failure of externally administered cy-
clic peptides to enter cells in sufficient quantity to sig-
nificantly affect TSG101!Gag binding and subse-
quently inhibit Gag egress. To improve cyclic peptide de-
livery into targeted mammalian cells, we attached a
short peptide sequence derived from the HIV Tat inter-
Figure 2. Tagging the genetically selected cyclic peptide
11 with a cysteine-modified HIV Tat peptide. The cysteine
of the corresponding linear peptide was protected with
4,4=-dithiodipyridine (Aldrithiol), and the peptide was cy-
clized as previously described. After purification by ether
precipitation, cysteine-modified Tat peptide was added at
2-fold excess to the cyclic peptide in DMSO solution. The
resulting Tat-tagged cyclic peptide was purified by HPLC,
and its identity was confirmed by MALDI MS. This process
was repeated for peptides 6 and 16.
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nalization domain; the synthesized Tat sequence, which
previously has been shown to aid the translocation of
a variety of proteins across the plasma membrane of
mammalian cells (7, 11), was attached to the cyclic pep-
tide through a disulfide bond between two cysteines.
This had been formed by modifying the nonrandom re-
gion of the cyclic peptide from SGW to CGW and by add-
ing a cysteine to the beginning of Tat (Figure 2).
Unlike its untagged parent, Tat-tagged cyclic peptide
11 at a 10 $M concentration inhibited VLP release by
(60% upon addition to cultures of 293T cells used in
the Gag-VLP assay. The same concentration of Tat-
tagged cyclic peptides 6 and 16 or of the Tat sequence
alone had no effect on VLP release (Figure 3, panel a).
The inhibitory effect of cyclic peptide 11 on VLP produc-
tion was found to be dose-dependent, with an IC50 of
7 $M (Figure 3, panel b). The dependence of the cyclic
peptide’s inhibition of VLP production on the TSG101 in-
teraction was tested using a mutant Gag protein that
lacks a PTAP motif (12) but still can be released as VLP,
although to a much lower extent than wild-type Gag
(ref 12; Figure 3, panel c). Whereas addition of Tat-cyclic
peptide 11 reduced the release of wild-type Gag as
VLP, we observed no effect of the peptide on release of
Figure 3. Gag VLP release assay. a) The effect of the Tat-tagged cyclic peptides on the level of Gag-GFP protein in the ly-
sate and in virus like particles (correlated to VLP release). Peptide 11 reduces VLP release by 60% at 10 $M. DMSO and
the HIV Tat sequence by itself were tested as negative controls. b) Effect of Tat-tagged cyclic peptide 11 on VLP release
(and the level of Gag-GFP in the lysate) at various concentrations. The IC50 of peptide 11 was determined to be 7 $M by
this method. c) Effect of Tat-tagged cyclic peptide 11 on VLP release of wild-type and PTAP mutant Gag constructs.
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the PTAP mutant Gag VLP (Figure 3, panel c). These
data indicate that cyclic peptide 11 specifically exerts
its inhibitory effect by interfering with PTAP-dependent
Gag budding.
Potentially, inhibitors of the TSG101!Gag interac-
tion may also interfere with the TSG101!HRS interac-
tion, affecting the cellular function of TSG101. In fact, we
detected similar reduction ("50%) in the amount of
HRS or Gag coprecipitated with TSG101 from 293T cell
extracts in the presence of 10$M Tat-tagged cyclic pep-
tide 11, whereas the Tat sequence by itself (negative
control) had no effect. In additional bacterial reverse
two-hybrid experiments, SICLOPPS plasmids coding for
cyclic peptides 6, 11, and 16 were introduced into an
HRS!UEV selection strain. Disruption of the TSG101!
Gag and TSG101!HRS interaction by each peptide was
comparedusingdrop spotting (Figure 4, panel a). The re-
sults also showed that both interactions were affected
to the same extent by the selected cyclic peptides. We
therefore set out to determine whether our genetically
selected viral budding inhibitor also affects the ability of
the TSG101!HRS complex to carry out its normal physi-
ological function, assaying Tat-tagged cyclic peptide 11
for its effects on the ligand-induced degradation of epi-
dermal growth factor receptor (EGRF) in HeLa cells (18).
There was no detectable inhibition of EFGR degradation
by Tat-tagged cyclic peptide 11 at 10 $M (Figure 4,
panel b), the same concentration that reduced VLP re-
lease by 60%. This result is consistent with earlier evi-
dence that the cellular level of TSG101 can be reduced
sufficiently by RNAi to affect viral release without pre-
venting cell growth (12).
The finding that interference with Tat-tagged cyclic
peptides inhibits viral budding by targeting the TSG101
interaction without precluding the essential actions of
TSG101 on receptor endocytosis and degradation sug-
gests the therapeutic potential of small molecules that
interferewith host protein functions recruited by viruses.
As the viral budding process relies on host proteins,
it may not be as readily circumvented by viral muta-
tions as are virus functions targeted by current HIV
countermeasures.
METHODS
Recombinant DNA Techniques. Escherichia coli cultures were
maintained in LB broth. DNA manipulations were performed
with E. coli DH5'-E (Invitrogen) cells. Plasmids were transformed
into E. coli by heat shock or electroporation. Restriction and
DNA-modifying enzymes were purchased from New England Bi-
oLabs. Oligonucleotides were purchased from Integrated DNA
Technologies. PCR purification and gel extraction kits were pur-
chased from Qiagen. DNA sequencing was performed at the
Nucleic Acid Facility of the Pennsylvania State University.
Bacterial Reverse Two-Hybrid System. To construct the het-
erodimeric RTHS, the p6 region of HIV Gag was cloned as a fu-
sion with a chimeric bacteriophage 434·P22 DNA binding re-
pressor. The UEV domain of TSG101 was cloned as a fusion with
the bacteriophage 434 repressor DNA binding domain. Both fu-
sions were placed under control of an IPTG-inducible promoter.
Antibiotics were provided at the following concentrations: ampi-
cillin 100 $g mL!1; chloroamphenicol 50 $g mL!1; kanamycin
50 $g mL!1; spectinomycin 50 $g mL!1. For chromosomal
markers, concentrations of antibiotics were reduced 2-fold. Mini-
Figure 4. Effects of cyclic peptides on HRS!TSG101 interaction. a) Ranking of SICLOPPS produced cyclic peptide 6 and 11,
in the p6!UEV and HRS!UEV strains by serial dilutions (2.5 mL of"10n cells/mL). The arabinose-deficient selection plate
has significantly lower intracellular cyclic peptide levels (arabinose is the promoter for SICLOPPS). Comparing the two
plates highlights the significant growth advantage conferred by the cyclic peptide inhibitors. b) Tat-tagged cyclic peptide
11 (10 $M) having no affect on EFGR degradation (a process controlled by HRS!TSG101) in HeLa cells, compared to the
wild-type and the HIV!Tat sequence alone.
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mal media A supplemented with 0.5% glycerol and 1 mM Mg-
SO4 was used for all genetic selections.
Genetic Selection for Cyclic Peptides. SICLOPPS SGWXXXXX
and SGWXXPXXPXX libraries (23, 24) were transformed into E.
coli strains containing integrated reporter and repressor con-
structs. Transformants were washed with minimal media A and
plated on minimal media A supplemented with 13 $M L-())-
arabinose, 2.5 mM 3-amino-1,2,4-triazole, 25 $M kanamycin,
and 30 $M IPTG. After incubation at 37 °C for 2!3 days, "200
surviving colonies were picked and restreaked onto the same
media with and without arabinose. Colonies that displayed an
arabinose dependent growth advantage were tested for IPTG-
dependent inhibition of growth (thus filtering out false positives
potentially arising through damage to the expression of SICLO-
PPS or fusion proteins). Plasmids from strains that passed the
above tests were retransformed into the original p6!UEV RTHS
strain and rechecked for phenotype retention. The 10 remaining
peptides were ranked for their activity by spotting serial dilu-
tions of the corresponding cells onto selective media, allowing
the conferred growth advantage to be compared at each dilution
level. The variable insert regions on the SICLOPPS plasmids
were PCR-amplified, and the DNA sequence of the active pep-
tides was determined.
We examined the target specificity of the four most active se-
lected cyclic peptides using a RTHS strain coding for the large
and small subunits of murine ribonucleotide reductase (RR). The
SICLOPPS plasmid of the p6!UEV selectants was transformed
into the RR RTHS strain, and the activity of each cyclic peptide
was ranked by drop spotting as before. The cyclic peptides that
act via specific disruption of the p6!UEV interaction are ex-
pected to be inactive in the new RR RTHS strain. However, if the
peptides confer arabinose-dependent growth advantage on the
RTHS strain by a different mechanism, the selectants would also
be active in the RR RTHS strain (which is identical to the p6!UEV
RTHS strain except for the RR homodimer). One of the four selec-
tants incurred a growth advantage (arabinose-dependent) on
the RR RTHS strain, showing a lack of specificity toward inhibit-
ing p6!UEV dimerization, and was therefore discarded.
Chemical Synthesis of Cyclic Peptides. Linear peptides were
synthesized at the Hershey Macromolecular Core Facility of the
Pennsylvania State University. Linear peptide 11 (WIYWNVSG,
10.0 mg, 9.8 $mol) was added to a solution of EDC (6 mg, 3
equiv, 29.4$mol) and HOAt (8.5 mg, 6 equiv, 58.8$mol) in DMF
(15 mL). The mixture was agitated at RT for 24 h. The solvent
was removed in vacuo, and the remaining residue was dissolved
in 500 $L of DMF and added dropwise to 10 mL of diethyl ether.
The resulting solid was separated by centrifugation and puri-
fied as outlined below (6.5 mg, 6.3 $mol, 64%). The procedure
was repeated for peptides 6 (WTNWYGSG) and 16 (WTLLVYSG).
Crude cyclic peptides were subjected to reverse-phase chroma-
tography (Partisil C-18 Magnum 9 [length 50 cm, particle size
10 $M] ODS-3 columns, Whatman) on a Waters HPLC system by
using a water/acetonitrile gradient with 0.1% trifluoroacetic
acid. Mass analysis was performed on aMariner mass spectrom-
eter (PerSeptive Biosystems, Framingham, MA).
Mammalian Cell Culture and Transfection. 293T cells were
maintained in DMEM supplemented with antibiotics and 10%
FBS (Invitrogen). Plasmid DNA transfections were performed by
using the FuGENE 6 reagent (Roche).
Antibodies,WesternBlotting, and Immunoprecipitation (IP).Pri-
mary antibodies used include polyclonal anti-GFP antibody
(Clontech), monoclonal anti-HRS antibody (Alexis Biochemical),
and monoclonal anti-Flag antibody (Sigma-Aldrich). HRP-
conjugated secondary antibodies were goat anti-mouse IgG
and goat anti-rabbit IgG (Santa Cruz Biotechnology). Western
blotting and Co-IP were performed using a procedure slightly
modified from that previously described (18). Flag-tagged
TSG101 was cotransfected with GFP-Gag into 293T cells for
48 h. Cells were lysed in the lysis buffer (150 mM NaCl, 50 mM
Tris-HCl, pH 7.5, 0.5% NP40) with protease inhibitors (protease
inhibitor tablet, Roche). Flag-TSG101 was captured using anti-
Flag antibody conjugated agarose beads (Sigma-Aldrich). The
immunoprecipitated complex was subjected to SDS!PAGE and
Western blotting.
Gag VLP Assay. A GFP-tagged wild-type Gag expression con-
struct (obtained from Dr. Marilyn Resh, Memorial Sloan-Kettering
Cancer Center, New York (30)) or a GFP-tagged PTAP minus mu-
tant Gag (PTAP changed to LIRL) construct (obtained from Dr.
Wesley Sundquist, University of Utah (12)) was transfected into
293T cells. Forty-eight hours after the initiation of transfection,
the culture supernatants were collected and filtered through a
0.45-$m-pore-size filter. Virus-like particles in the culture super-
natants were isolated by ultracentrifugation through a cushion
of 20% sucrose at 45,000 rpm for 90 min at 4 °C using a Beck-
man SW50.1Ti rotor. The viral particles in the pellets were resus-
pended in SDS sample loading buffer and subjected to
SDS!PAGE and Western blotting.
Ligand-Induced EGFR Downregulation Assay. 293T cells were
seeded in six-well plates at 5 # 105 per well and transfected
with 50 ng of pCDNA3-EGFR (obtained from Dr. Hamid Band,
Northwestern University (28)). Forty-eight hours after the initia-
tion of transfection, the cells were starved in serum-free medium
for 1 h and were either mock-treated as controls or incubated
with EGF (Sigma-Aldrich) at a concentration of 150 ng mL!1 in
37 °C for 90 min. Cells were then washed with cold PBS and im-
mediately lysed. Lysates were subjected to SDS!PAGE and
Western blotting using rabbit anti-EGFR antibody (Santa Cruz
Biotechnology).
Acknowledgment: These investigations were supported by
grants from the Defense Research Projects Agency (DARPA) to
S.N.C. and S.J.B and from the Defense Threat Reduction Agency
(DTRA) to S.N.C.
REFERENCES
1. Clavel, F., and Hance, A. J. (2004) HIV drug resistance, N. Engl.
J. Med. 350, 1023–1035.
2. Rossi, J. J., June, C. H., and Kohn, D. B. (2007) Genetic therapies
against HIV, Nat. Biotechnol. 25, 1444–1454.
3. Freed, E. O. (2004) HIV-1 and the host cell: an intimate association,
TrendsMicrobiol. 12, 170–177.
4. Trkola, A. (2004) HIV-host interactions: vital to the virus and key to
its inhibition, Curr. Opin. Microbiol. 7, 407–411.
5. Freed, E. O. (2004) Mechanisms of enveloped virus release, Virus
Res. 106, 85–86.
6. Gottlinger, H. G. (2001) The HIV assemblymachine, AIDS 15, Suppl.
5S13–20.
7. Huang, M., Orenstein, J. M., Martin, M. A., and Freed, E. O. (1995)
p6Gag is required for particle production from full-length human im-
munodeficiency virus type 1 molecular clones expressing pro-
tease, J. Virol. 69, 6810–6818.
8. Smith, A. J., Cho, M. I., Hammarskjold, M. L., and Rekosh, D. (1990)
Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol
expressed from a simian virus 40 late replacement vector are effi-
ciently processed and assembled into viruslike particles, J. Virol.
64, 2743–2750.
9. Morita, E., and Sundquist, W. I. (2004) Retrovirus budding, Annu.
Rev. Cell Dev. Biol. 20, 395–425.
10. Freed, E. O. (2002) Viral late domains, J. Virol. 76, 4679–4687.
11. Gottlinger, H. G., Dorfman, T., Sodroski, J. G., and Haseltine, W. A.
(1991) Effect of mutations affecting the p6 gag protein on human
immunodeficiency virus particle release, Proc. Natl. Acad. Sci. U.S.A.
88, 3195–3199.
ARTICLE
www.acschemicalbiology.org VOL.3 NO.12 • 757–764 • 2008 763
12. Garrus, J. E., von Schwedler, U. K., Pornillos, O. W., Morham, S. G.,
Zavitz, K. H.,Wang,H. E.,Wettstein, D. A., Stray, K.M., Cote,M., Rich,
R. L., Myszka, D. G., and Sundquist, W. I. (2001) Tsg101 and the
vacuolar protein sorting pathway are essential for HIV-1 budding,
Cell 107, 55–65.
13. Martin-Serrano, J., Zang, T., and Bieniasz, P. D. (2001) HIV-1 and
Ebola virus encode small peptide motifs that recruit Tsg101 to sites
of particle assembly to facilitate egress, Nat. Med. 7, 1313–1319.
14. VerPlank, L., Bouamr, F., LaGrassa, T. J., Agresta, B., Kikonyogo, A.,
Leis, J., and Carter, C. A. (2001) Tsg101, a homologue of ubiquitin-
conjugating (E2) enzymes, binds the L domain in HIV type 1
Pr55(Gag), Proc. Natl. Acad. Sci. U.S.A. 98, 7724–7729.
15. Li, L., and Cohen, S. N. (1996) Tsg101: a novel tumor susceptibility
gene isolated by controlled homozygous functional knockout of al-
lelic loci in mammalian cells, Cell 85, 319–329.
16. Katzmann, D. J., Odorizzi, G., and Emr, S. D. (2002) Receptor down-
regulation andmultivesicular-body sorting,Nat. Rev. Mol. Cell. Biol.
3, 893–905.
17. Bache, K. G., Brech, A., Mehlum, A., and Stenmark, H. (2003) Hrs
regulatesmultivesicular body formation via ESCRT recruitment to en-
dosomes, J. Cell. Biol. 162, 435–442.
18. Lu,Q., Hope, L.W., Brasch,M., Reinhard, C., andCohen,S.N. (2003)
TSG101 interaction with HRSmediates endosomal trafficking and
receptor down-regulation, Proc. Natl. Acad. Sci. U.S.A. 100, 7626–
7631.
19. Pornillos, O., Higginson, D. S., Stray, K. M., Fisher, R. D., Garrus, J. E.,
Payne, M., He, G. P., Wang, H. E., Morham, S. G., and Sundquist,
W. I. (2003) HIV Gagmimics the Tsg101-recruiting activity of the hu-
man Hrs protein, J. Cell. Biol. 162, 425–434.
20. Goff, A., Ehrlich, L. S., Cohen, S. N., and Carter, C. A. (2003) Tsg101
control of human immunodeficiency virus type 1Gag trafficking and
release, J. Virol. 77, 9173–9182.
21. Liu, F., Stephen, A. G., Fisher, R. J., and Burke, T. R., Jr. (2008) Pro-
tected aminooxyprolines for expedited library synthesis: applica-
tion to Tsg101-directed proline-oxime containing peptides, Bioorg.
Med. Chem. Lett. 18, 1096–1101.
22. Liu, F., Stephen, A. G., Waheed, A. A., Aman, M. J., Freed, E. O.,
Fisher, R. J., andBurke, T. R., Jr. (2008) SARbyoxime-containingpep-
tide libraries: application to Tsg101 ligand optimization, ChemBio-
Chem 9, 2000–2004.
23. Scott, C. P., Abel-Santos, E., Jones, A. D., and Benkovic, S. J. (2001)
Structural requirements for the biosynthesis of backbone cyclic pep-
tide libraries, Chem. Biol. 8, 801–815.
24. Tavassoli, A., and Benkovic, S. J. (2007) Split-intein mediated circu-
lar ligation used in the synthesis of cyclic peptide libraries in E. coli,
Nat. Protoc. 2, 1126–1133.
25. Horswill, A. R., Savinov, S. N., and Benkovic, S. J. (2004) A system-
atic method for identifying small-molecule modulators of protein-
protein interactions, Proc. Natl. Acad. Sci. U.S.A. 101, 15591–
15596.
26. Tavassoli, A., and Benkovic, S. J. (2005) Genetically selected cyclic-
peptide inhibitors of AICAR transformylase homodimerization, An-
gew. Chem., Int. Ed. Engl. 44, 2760–2763.
27. Haldimann, A., andWanner, B. L. (2001) Conditional-replication, in-
tegration, excision, and retrieval plasmid-host systems for gene
structure-function studies of bacteria, J. Bacteriol. 183, 6384–
6393.
28. Pornillos, O., Alam, S. L., Davis, D. R., and Sundquist, W. I. (2002)
Structure of the Tsg101 UEV domain in complex with the PTAPmo-
tif of the HIV-1 p6 protein, Nat. Struct. Biol. 9, 812–817.
29. Scarlata, S., and Carter, C. (2003) Role of HIV-1 Gag domains in vi-
ral assembly, Biochim. Biophys. Acta 1614, 62–72.
30. Hermida-Matsumoto, L., and Resh, M. D. (2000) Localization of hu-
man immunodeficiency virus type 1 Gag and Env at the plasma
membrane by confocal imaging, J. Virol. 74, 8670–8679.
764 VOL.3 NO.12 • 757–764 • 2008 www.acschemicalbiology.orgTAVASSOLI ET AL.
